InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers... Show more
INFU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 40 cases where INFU's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INFU's RSI Oscillator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 25, 2025. You may want to consider a long position or call options on INFU as a result. In of 110 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for INFU just turned positive on July 25, 2025. Looking at past instances where INFU's MACD turned positive, the stock continued to rise in of 59 cases over the following month. The odds of a continued upward trend are .
INFU moved above its 50-day moving average on July 25, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INFU advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 153 cases where INFU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for INFU crossed bearishly below the 50-day moving average on July 17, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INFU declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. INFU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.628) is normal, around the industry mean (24.694). P/E Ratio (195.127) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (1.598) is also within normal values, averaging (43.573).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INFU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
a manufacturer of external ambulatory infusion pumps
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, INFU has been loosely correlated with NVST. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if INFU jumps, then NVST could also see price increases.
Ticker / NAME | Correlation To INFU | 1D Price Change % | ||
---|---|---|---|---|
INFU | 100% | +1.69% | ||
NVST - INFU | 40% Loosely correlated | +0.63% | ||
ALGN - INFU | 38% Loosely correlated | N/A | ||
RDNT - INFU | 37% Loosely correlated | +2.54% | ||
QDEL - INFU | 37% Loosely correlated | +4.03% | ||
TMCI - INFU | 36% Loosely correlated | -1.55% | ||
More |